Nova Patents
AT534739T

Anti-interferon-alpha antibodies

Abstract

This record has no abstract on file.

Term

Term ended

Expired 29 January 2022, 4.7 years ago.

  1. Priority
  2. Filed
  3. Granted
  4. Expired
  5. Today

76 members in 18 offices

This recordMember, by publication datePriority claim8 more offices are in the list below

Priority claims3

Priority claims
DocumentOfficeKindDate
27077501United States of AmericaP
4489602United States of AmericaA
0202709United States of AmericaW

Members76

Family members, oldest first
DocumentOfficeKind
CA2437161A1CanadaA1
WO02066649A2World Intellectual Property Organization (WIPO)A2
AU2002306432C1AustraliaC1
AU2002306432C9AustraliaC9
WO02066649A3World Intellectual Property Organization (WIPO)A3
US2003166228A1United States of AmericaA1
KR20030081461ARepublic of KoreaA
WO02066649A8World Intellectual Property Organization (WIPO)A8
EP1362105A2European Patent Office (EPO)A2
MXPA03007529AMexicoA
IL157170A0IsraelA0
CN1492930AChinaA
JP2004533217AJapanA
RU2003128365ARussian FederationA
US7087726B2United States of AmericaB2
NZ527338ANew ZealandA
AU2002306432B2AustraliaB2
AU2006252117A1AustraliaA1
US2007048311A1United States of AmericaA1
US2007059309A1United States of AmericaA1
RU2314317C2Russian FederationC2
EP2065467A2European Patent Office (EPO)A2
JP2009131257AJapanA
US7582445B2United States of AmericaB2
EP2065467A3European Patent Office (EPO)A3
KR20090107095ARepublic of KoreaA
JP4384853B2JapanB2
KR100940968B1Republic of KoreaB1
KR20100095641ARepublic of KoreaA
CN101857636AChinaA
IL157170AIsraelA
EP2292301A2European Patent Office (EPO)A2
AU2011200707A1AustraliaA1
US7910707B2United States of AmericaB2
EP2301629A2European Patent Office (EPO)A2
EP2305714A2European Patent Office (EPO)A2
KR20110066232ARepublic of KoreaA
US2011206663A1United States of AmericaA1
HK1149567AHong Kong, ChinaA
HK1149567A1Hong Kong, ChinaA1
US2011268727A1United States of AmericaA1
EP1362105B1European Patent Office (EPO)B1
AT534739TThis recordAustriaT
ATE534739T1AustriaT1
PT1362105EPortugalE
EP2292301A3European Patent Office (EPO)A3
DK1362105T3DenmarkT3
EP2305714A3European Patent Office (EPO)A3
SI1362105T1SloveniaT1
ES2378062T3SpainT3
HK1153967AHong Kong, ChinaA
HK1153967A1Hong Kong, ChinaA1
EP2301629A3European Patent Office (EPO)A3
KR101154643B1Republic of KoreaB1
US2012244148A1United States of AmericaA1
CN101857636BChinaB
JP2012245008AJapanA
KR20120137512ARepublic of KoreaA
US8349331B2United States of AmericaB2
CN102993303AChinaA
US2013084295A1United States of AmericaA1
AU2011200707B2AustraliaB2
US8557967B2United States of AmericaB2
EP2065467B1European Patent Office (EPO)B1
JP5349018B2JapanB2
US2013309236A1United States of AmericaA1
DK2065467T3DenmarkT3
ES2436787T3SpainT3
PT2065467EPortugalE
SI2065467T1SloveniaT1
EP2292301B1European Patent Office (EPO)B1
EP2065467B9European Patent Office (EPO)B9
ES2461148T3SpainT3
DK2065467T5DenmarkT5
KR101413907B1Republic of KoreaB1
CA2437161CCanadaC